Drugs / LEAP2
LEAP2
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04897984 | May → Jun 2021 | obesity disorder | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| Phase 0 | NCT04621409 | Nov 2020 → Feb 2021 | obesity disorder | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07171723 | Sep → Dec 2025 overdue | obesity disorder | University Hospital, Gentofte, Copenhagen | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06254365 | Feb 2024 → Sep 2025 overdue | obesity disorder | University Hospital, Gentofte, Copenhagen | Active not recruiting | No outcome recorded |
| — | NCT05603598 | Aug 2022 → May 2023 | obesity disorder | University Hospital, Gentofte, Copenhagen | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEAP2 | “The study aim to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in...” NCT04621409 ↗5“This study aims to investigate the kinetics of exogenous LEAP2 in healthy subjects.” NCT04897984 ↗ “IV infusion of LEAP2, approximately 5.5 hours” NCT05603598 ↗ |
| Known as | liver-enriched antimicrobial peptide 2 | “The study aim to delineate the effects of the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2) on postprandial glucose metabolism and food intake in...” NCT04621409 ↗2“the gene encoding liver enriched antimicrobial peptide 2 (LEAP2), a naturally occurring human peptide, was significantly upregulated compared to baseline expression.” NCT06254365 ↗ “the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2)” NCT05603598 ↗ |
| Known as | Liver-Expressed Antimicrobial Peptide 2 | “Continuous intravenous infusion of LEAP2 (Liver-Expressed Antimicrobial Peptide 2), an endogenous inverse agonist and competitive antagonist of the ghrelin receptor (GHSR),...” NCT07171723 ↗ |
| Action | Inhibit | “LEAP-2 was recently shown to antagonize ghrelin function in response to feeding in mice.” NCT04621409 ↗ |
| Modality | Peptide | “the naturally occurring peptide liver-enriched antimicrobial peptide 2 (LEAP-2)” NCT04621409 ↗ |
| Route | Intravenous | “IV infusion of LEAP2, approximately 5 hours” NCT04621409 ↗ |
| Target | GHSR | “an endogenous inverse agonist and competitive antagonist of the GHSR” NCT07171723 ↗ |